Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
Reducing Surgical Complications in Newly Diagnosed Lung Cancer Patients Who Smoke Cigarettes
Sponsor: Alliance for Clinical Trials in Oncology
Enrolling: Male and Female Patients
IRB Number: AAAR9502
U.S. Govt. ID: NCT02856581
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: This randomized phase III trial studies how well management of a tobacco treatment intervention works in reducing surgical complications in patients with newly diagnosed lung cancer who smoke cigarettes. Management of a tobacco treatment intervention compares varenicline (a drug that reduces the craving and withdrawal symptoms that occur with abstinence from nicotine) and behavioral interventions consisting of a brief clinician-delivered intervention and tobacco quitline tobacco cessation service available through a toll-free telephone number follow-up with placebo (a pill with no active medication) along with similar behavioral interventions. It is not yet known whether management of a tobacco treatment intervention is more effective in reducing surgical complications than placebo.
This study is closed
Investigator
Bryan Stanifer, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have a new diagnosis of lung cancer and are seeking surgical consult? Yes No
Have you smoked daily or nearly every day in the previous 6 months? Yes No
Are you motivated to stop smoking? Yes No
Can you complete study questionnaires in English? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder




For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162